AstraZeneca's Tumor Drug Shows Promising Results
Posted on: Wednesday, 8 November 2006, 15:00 CST
AstraZeneca's experimental cancer drug AZD6244 has shown a stabilizing effect on patients with advanced solid cancer tumors in preliminary trials, and is now being tested in phase II clinical trials.
The drug, which AstraZeneca has in-licensed from Array BioPharma, inhibits MEK 1/2, an enzyme which regulates cell proliferation and survival. Activation of this pathway has been implicated in a number of cancers including lung, pancreatic, colon, melanoma and thyroid cancer.
Professor Alex Adjei, who oversaw the study at the Mayo Clinic, University of Colorado Health Sciences Center and Fox Chase Cancer Center, said: "Results from this second part of the trial demonstrate that a dose of 100mg of AZD6244 is well tolerated, produces a high incidence of long-lasting stable disease, and is associated with a profound inhibition of the cell signaling protein pERK and a reduction in cell proliferation - which indicates that the drug is working against the tumors."
The researchers tested biopsy tissue taken from the patients both before and after dosing. They found that the pERK protein was reduced by 77%. They also looked at another protein, Ki-67, which is used as a marker for cell proliferation. After dosing, there was a reduction in Ki-67 in nine out of 20 patients, and in five of those nine patients the reduction was at least 50% or more.
Source: Datamonitor
Related Articles
- Amrubicin(R) Receives FDA Orphan Drug Designation for the Treatment of Small Cell Lung Cancer
- ArQule Enrolls First Patient in Phase 1/2 Clinical Trial Program of ARQ 197 in Non-Small Cell Lung Cancer
- Introgen's P53 Immunotherapy Drug Candidate to Advance Into Second Phase 2 Clinical Trial in Small Cell Lung Cancer With National Cancer Institute
- Geron Initiates Clinical Trial of Telomerase Inhibitor Drug in Combination With Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer
- Poniard Pharmaceuticals Announces Treatment of First Patient With Picoplatin in Pivotal Phase 3 Small Cell Lung Cancer Trial
- Threshold Pharmaceuticals Initiates Phase 2 Clinical Trial Evaluating Glufosfamide in Patients With Recurrent, Sensitive Small Cell Lung Cancer
- View Scientific Rationale for Novel Therapeutics in Lung Cancer, And the Results of Clinical Trials to Date Inside 'Triple Analysis: Non Small Cell Lung Cancer, Protein Kinase Inhibitors & Anti-Angiogenic Agents'
- Sunesis Pharmaceuticals Initiates Phase II Clinical Trial of SNS-595 in Non-Small Cell Lung Cancer
- AVAX Technologies Announces the Filing of IND for the Treatment of Patients With Non Small Cell Lung Cancer
- Cancer Drug May Help Sickle Cell Patients
 |
 |
User Comments (0)
RSS Feeds